Researchers in Brazil have reported the detection of two emerging ketamine-related substances in oral-fluid samples collected from people attending recreational events, providing new evidence for forensic toxicology and drug surveillance.
The study, published on 19 November 2026 in the journal Forensic Toxicology, was conducted by Leonardo Costalonga Rodrigues and colleagues from Brazilian research institutions, including the University of Campinas, with international collaboration.
The researchers investigated deschloroketamine (DCK) and 2-fluoro-deschloroketamine (2-FDCK), substances structurally related to ketamine.
These compounds belong to a group of emerging psychoactive substances that can present analytical challenges because their chemical structures resemble those of established drugs.
Oral fluid is increasingly investigated as a biological sample for detecting recent drug exposure. Compared with some other specimen types, it can be collected relatively easily and under direct observation.
The researchers collected samples from volunteers attending 14 festivals and recreational events in Brazil between October 2023 and May 2025.
A total of 408 samples that had screened positive initially were selected for further analysis.
The laboratory used dispersive liquid–liquid microextraction followed by liquid chromatography–tandem mass spectrometry (LC–MS/MS) to identify and quantify ketamine, two metabolites and the emerging analogues.
Of the 408 screened samples, 198, approximately 48%, were confirmed positive for at least one of the five target compounds.
Ketamine and its metabolite 6-hydroxy-norketamine were among the most frequently detected substances.
Importantly, DCK was identified in four samples, while 2-FDCK was detected in two samples.
According to the researchers, this represents the first reported detection of these compounds in authentic oral-fluid specimens worldwide.
The study also found differences between laboratory findings and participants' reported substance use.
Only 41% of ketamine-positive participants reported using ketamine, while none reported intentionally consuming DCK or 2-FDCK.
However, the absence of reported intentional use does not establish whether exposure occurred unknowingly, through misidentified products or for other reasons.
The findings demonstrate the value of analytical methods capable of detecting emerging drug analogues alongside established substances.
For forensic toxicology laboratories, expanding analytical coverage may help identify substances that would otherwise be overlooked during targeted testing.
Nevertheless, the research has important limitations. The 408 specimens were selected following initial positive screening, so the results cannot be interpreted as prevalence estimates for all festival attendees or the general Brazilian population.
Detection in oral fluid also does not independently establish impairment, the amount consumed or the precise timing of exposure.
The study highlights the potential of oral-fluid testing as a complementary approach for monitoring emerging psychoactive substances and improving forensic drug surveillance.